What has ibogaine done for alcohol use?

The human evidence here is thinner than for opioids, and saying so plainly is the useful starting point. It consists of one nine-person safety pilot published in 2026 [1] and a retrospective review of clinic records from Brazil [2]. Neither was designed to establish whether ibogaine helps people drink less.

The state of the evidence

Most of what is written about ibogaine concerns opioids, and the research base reflects that. The opioid literature includes a 191-person inpatient series, a twelve-month follow-up study and a hospital study with detailed cardiac measurement.

Alcohol has nothing comparable. A 2026 review of thirty years of human ibogaine research concluded that the positive efficacy data across the whole field comes mostly from uncontrolled studies [4], and the alcohol subset is smaller and less controlled than the opioid one.

This does not mean ibogaine does nothing for alcohol use. It means the question has barely been asked in a form that could answer it, and anyone presenting alcohol outcomes with the confidence of established treatment is going beyond the literature.

The nine-person pilot

The most direct study is a 2026 open-label pilot in nine adults with moderate to severe alcohol use disorder [1].

Its primary purpose was safety rather than effect. The outcomes it was built to measure were the corrected QT interval, vital signs, laboratory results, adverse effects and psychiatric assessment, with alcohol and substance use recorded as secondary [1].

The design reflects that caution. The first three volunteers received ascending doses from 20 to 320 milligrams, and the following six received a single 400 milligram dose [1]. Participants were hospitalised for 24 to 48 hours before dosing with continuous monitoring [1].

Those doses are markedly lower than the weight-based doses used in opioid studies, where 10 milligrams per kilogram for a typical adult runs to several times this amount. The pilot was establishing whether a dose could be given safely at all, not matching what clinics administer.

What that pilot found

On safety, QT interval changes occurred in five of the nine participants, including both transient lengthening and shortening [1]. There were mild to moderate changes in blood pressure [1].

Common adverse effects were drowsiness, nausea and anxiety, mostly at the higher doses between 240 and 400 milligrams [1]. No serious adverse effects occurred, and two participants needed medication for psychomotor agitation, insomnia and raised blood pressure [1].

Cardiac changes in five of nine, at doses well below those used in treatment, is the finding to carry forward. The authors call for rigorous cardiovascular screening and continuous monitoring, and for randomised controlled trials [1].

On drinking, most participants reported reduced alcohol use, and five of the nine completed the study [1]. The authors themselves name motivation and placebo as possible explanations [1].

That last point is worth dwelling on. The researchers who ran the study decline to attribute the reduction to the drug, in a paper reporting their own results. A page that states the matter more confidently than they do is not reading the same evidence.

The Brazilian records review

The second source is larger and older. Researchers reviewed clinic records for 75 former users of alcohol, cannabis, cocaine and crack in Brazil, where ibogaine was unregulated [2].

Treatment combined ibogaine with psychotherapy under a physician's supervision [2]. At the time the data was collected, 61 per cent of participants were abstinent [2].

Median self-reported abstinence was 5.5 months after a single treatment and 8.4 months after multiple treatments, both longer than the abstinence periods those individuals had achieved before their first session [2].

The within-person comparison is the most useful feature of that study. Comparing a person's abstinence after treatment with their own history before it controls for some of what distinguishes them from the general population, though not for the passage of time or for the decision to seek help.

What a records review cannot show

Several limits apply, and they are structural rather than incidental.

The participants were 72 per cent poly-drug users [2], so this is not a study of alcohol alone. Abstinence was self-reported and collected retrospectively from records rather than verified prospectively.

There was no control group [2]. People who seek out and pay for an intensive treatment differ from those who do not, in motivation, resources and support, and all three predict better outcomes independently.

Treatment also included psychotherapy [2], so the result belongs to a combination rather than to ibogaine by itself. That pattern recurs across this literature and is the single most common thing omitted when results are summarised.

What the animal work shows

Rodent research is more consistent than the human work, and it is rodent research.

Across several laboratories, ibogaine reduced self-administration of morphine, heroin, cocaine and alcohol in rodents, and reduced the signs of precipitated withdrawal [3]. Alcohol is included in that list, which is part of why the question is asked at all.

A reduction in a rat's drinking is a genuine finding about a mechanism worth investigating. It is not evidence about a person, and the gap between the two is exactly where this field has struggled for thirty years.

Why opioids have been studied more

The imbalance has a reason behind it, and it is informative.

Ibogaine's most reliably reported human effect is the rapid reduction of opioid withdrawal, which is dramatic, happens within hours and is measurable with established scales. That makes it both easier to study and more obviously valuable, since opioid withdrawal is a specific barrier people cannot get past.

Alcohol use disorder has no equivalent single barrier. Its treatment is a longer process, and the outcomes that matter are measured in months of drinking behaviour rather than in hours of symptom relief.

Approved treatments for alcohol use disorder also already exist, which raises the bar for exposing participants to a drug with ibogaine's cardiac profile.

Alcohol withdrawal is a different problem

One point deserves emphasis because the opioid framing can mislead.

Severe alcohol withdrawal can be fatal on its own, through seizures and delirium tremens, in a way opioid withdrawal generally is not. It is a medical emergency requiring its own treatment, typically with benzodiazepines, under supervision.

That matters here for a specific reason. Benzodiazepines appear in the exclusion lists for ibogaine protocols [5], which puts the standard treatment for alcohol withdrawal in tension with the preparation for ibogaine.

Anyone physically dependent on alcohol therefore faces a sequencing problem that does not arise for opioids, and it is a question for a physician rather than a provider.

Reading what a provider says about alcohol

Because the evidence is thin, the gap between what is known and what is advertised is wider here than for opioids. A few habits help in reading any particular claim.

The first is to ask which population a figure comes from. An abstinence percentage drawn from the Brazilian review describes a group that was 72 per cent poly-drug users and received psychotherapy alongside treatment [2]. Presented as an alcohol result, it quietly changes meaning.

The second is to notice whether a number has a source at all. Success rates appear on provider pages without citation far more often than they appear in journals, and the published figures are attached to study designs that the pages describing them rarely mention.

The third is to check what the claim says about cause. The authors of the 2026 pilot reported reduced drinking and then named motivation and placebo as possible explanations [1]. A provider citing that study while omitting its authors' own caution has edited the finding rather than reported it.

The fourth concerns withdrawal. Marketing sometimes carries the opioid framing across to alcohol, implying that ibogaine removes alcohol withdrawal the way it is reported to reduce opioid withdrawal. No human study has shown that, and alcohol withdrawal is dangerous in ways that make the assumption worth questioning directly.

A provider who distinguishes between opioid and alcohol evidence, unprompted, is describing the literature accurately. One who treats them as a single body of work is not, and the vetting standard sets out what else is worth asking.

What a reader can take from this

The honest summary is short. Nine people have been studied prospectively, with safety as the main outcome and cardiac changes in five of them. Seventy-five more were reviewed retrospectively, most of them using several substances, after treatment that included psychotherapy.

Both reported reduced use. Neither can show that ibogaine caused it, and the authors of the newer study say so directly [1].

The cardiac risk, meanwhile, is as well established for this group as for any other. It does not scale down with the strength of the evidence for benefit, and that asymmetry is the heart of the decision: the harm is measured precisely and the benefit is not.

For someone whose drinking has not responded to the treatments that do have controlled evidence behind them, that asymmetry may still be worth accepting. That is a judgement about a particular life rather than a conclusion from the literature, and it is better made with a physician who knows the person's heart, liver and medication list than from any page.

It is also worth separating two questions that often merge. One is whether ibogaine reduces the urge to drink. The other is whether it helps someone stay stopped. The Brazilian data speaks to the second, since it measured months of abstinence [2], while the rodent work speaks to the first, since it measured self-administration [3]. Neither establishes the other, and a treatment could plausibly do one without the other.

The repeat-treatment finding sits awkwardly between them. Median abstinence was longer after multiple treatments than after one [2], which could mean the effect accumulates, or that people who returned for a second session were those for whom the first had helped. A retrospective design cannot distinguish those readings, and the difference matters to anyone deciding whether to plan for more than one treatment.

Where the research goes next

The pilot's authors name the next step themselves: randomised controlled trials, with rigorous cardiovascular screening and continuous monitoring [1].

Two further questions would help. Whether the doses used in treatment carry a different cardiac profile from the lower doses tested in the pilot. And whether any effect on drinking survives comparison with the psychotherapy that has accompanied it in every human study so far.

The evidence overview sets these findings beside the opioid data, where the research is further along.

Frequently asked questions

Has ibogaine been studied for alcohol use disorder?

Once prospectively, in a nine-person open-label safety pilot published in 2026 [1], and once retrospectively in 75 clinic records from Brazil in which most participants used several substances [2].

Did people drink less afterwards?

Most participants in the pilot reported reduced alcohol use, and its authors name motivation and placebo as possible explanations [1]. In the Brazilian review, 61 per cent were abstinent at the time of data collection [2].

Is ibogaine safer at the lower doses used in the alcohol pilot?

QT interval changes still occurred in five of the nine participants at those doses [1]. The authors call for rigorous cardiovascular screening and continuous monitoring regardless [1].

Why is there more research on opioids than alcohol?

Ibogaine's most reliably reported human effect is rapid reduction of opioid withdrawal, which is measurable within hours using established scales. Alcohol outcomes are measured in months of drinking behaviour, which is harder to study, and approved treatments for alcohol use disorder already exist.

Can someone go through alcohol withdrawal with ibogaine?

Severe alcohol withdrawal can be life-threatening and is treated as a medical emergency in its own right. Benzodiazepines, the standard treatment for it, appear among the exclusions in ibogaine protocols [5].